JP2009518406A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009518406A5 JP2009518406A5 JP2008544422A JP2008544422A JP2009518406A5 JP 2009518406 A5 JP2009518406 A5 JP 2009518406A5 JP 2008544422 A JP2008544422 A JP 2008544422A JP 2008544422 A JP2008544422 A JP 2008544422A JP 2009518406 A5 JP2009518406 A5 JP 2009518406A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- cancer
- patient
- estrogen
- paclitaxel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 229930012538 Paclitaxel Natural products 0.000 claims 7
- 229960001592 paclitaxel Drugs 0.000 claims 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 7
- 229940011871 estrogen Drugs 0.000 claims 6
- 239000000262 estrogen Substances 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 229940041181 antineoplastic drug Drugs 0.000 claims 5
- 210000002966 serum Anatomy 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 102000015694 estrogen receptors Human genes 0.000 claims 4
- 108010038795 estrogen receptors Proteins 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229920001308 poly(aminoacid) Polymers 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 108010020346 Polyglutamic Acid Proteins 0.000 claims 2
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 claims 2
- 238000002657 hormone replacement therapy Methods 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 229920002643 polyglutamic acid Polymers 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 230000002280 anti-androgenic effect Effects 0.000 claims 1
- 239000000051 antiandrogen Substances 0.000 claims 1
- 229960005309 estradiol Drugs 0.000 claims 1
- 229930182833 estradiol Natural products 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74272505P | 2005-12-06 | 2005-12-06 | |
| US81422106P | 2006-06-16 | 2006-06-16 | |
| PCT/US2006/046281 WO2007067498A1 (en) | 2005-12-06 | 2006-12-05 | Estrogen cancer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009518406A JP2009518406A (ja) | 2009-05-07 |
| JP2009518406A5 true JP2009518406A5 (enExample) | 2010-01-28 |
Family
ID=37891993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008544422A Pending JP2009518406A (ja) | 2005-12-06 | 2006-12-05 | エストロゲン癌療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20070167349A1 (enExample) |
| EP (1) | EP1957065A1 (enExample) |
| JP (1) | JP2009518406A (enExample) |
| KR (1) | KR20080074202A (enExample) |
| CA (1) | CA2630553A1 (enExample) |
| PE (1) | PE20070701A1 (enExample) |
| RU (1) | RU2008127309A (enExample) |
| TW (1) | TWI322010B (enExample) |
| WO (1) | WO2007067498A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010014250A1 (en) * | 2008-08-01 | 2010-02-04 | Cell Therapeutics, Inc. | Prediction of cancer therapy based on cathespin b levels |
| WO2010014249A1 (en) * | 2008-08-01 | 2010-02-04 | Cell Therapeutics, Inc. | Cancer therapy comprising estrogen inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4942184A (en) * | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
| GB9120653D0 (en) * | 1991-09-27 | 1991-11-06 | Procter & Gamble | Dispensing agent |
| US5731316A (en) * | 1996-01-30 | 1998-03-24 | The Stehlin Foundation For Cancer Research | Derivatives of camptothecin and methods of treating cancer using these derivatives |
| US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
| US5977163A (en) * | 1996-03-12 | 1999-11-02 | Pg-Txl Company, L. P. | Water soluble paclitaxel prodrugs |
| CA2366697A1 (en) * | 1999-02-26 | 2000-08-31 | Larry Helson | Treatment regimen for hormone-sensitive cancers |
| JP2003511423A (ja) * | 1999-10-12 | 2003-03-25 | セル・セラピューティックス・インコーポレーテッド | ポリグルタメート−治療薬コンジュゲートの製造 |
-
2006
- 2006-12-05 WO PCT/US2006/046281 patent/WO2007067498A1/en not_active Ceased
- 2006-12-05 RU RU2008127309/15A patent/RU2008127309A/ru not_active Application Discontinuation
- 2006-12-05 EP EP06838948A patent/EP1957065A1/en not_active Withdrawn
- 2006-12-05 KR KR1020087015960A patent/KR20080074202A/ko not_active Withdrawn
- 2006-12-05 PE PE2006001549A patent/PE20070701A1/es not_active Application Discontinuation
- 2006-12-05 CA CA002630553A patent/CA2630553A1/en not_active Abandoned
- 2006-12-05 US US11/634,356 patent/US20070167349A1/en not_active Abandoned
- 2006-12-05 TW TW095145182A patent/TWI322010B/zh not_active IP Right Cessation
- 2006-12-05 JP JP2008544422A patent/JP2009518406A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Seymour et al. | Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma | |
| Jia et al. | Multi-functional self-assembly nanoparticles originating from small molecule natural product for oral insulin delivery through modulating tight junctions | |
| Harper et al. | Advances in platinum chemotherapeutics | |
| Wang et al. | PEG–PCL based micelle hydrogels as oral docetaxel delivery systems for breast cancer therapy | |
| Ding et al. | Multilayered mucoadhesive hydrogel films based on thiolated hyaluronic acid and polyvinylalcohol for insulin delivery | |
| Wang et al. | Delivery of folic acid-modified liposomal curcumin for targeted cervical carcinoma therapy | |
| CA2713813C (en) | Intralymphatic chemotherapy drug carriers | |
| WO2009152691A1 (zh) | 聚乙二醇修饰壳寡糖脂肪酸嫁接物及制备方法和应用 | |
| JP2011513412A (ja) | ポリマーパクリタキセル結合体を含む癌を治療するための薬学組成物 | |
| Mao et al. | Nanoparticle-mediated delivery of Tanshinone IIA reduces adverse cardiac remodeling following myocardial infarctions in a mice model: role of NF-κB pathway | |
| Hong et al. | Reducing posttreatment relapse in cleft lip palatal expansion using an injectable estrogen–nanodiamond hydrogel | |
| Liu et al. | An Osteoimmunomodulatory Biopatch Potentiates Stem Cell Therapies for Bone Regeneration by Simultaneously Regulating IL‐17/Ferroptosis Signaling Pathways | |
| Zhang et al. | Targeted micelles with chemotherapeutics and gene drugs to inhibit the G1/S and G2/M mitotic cycle of prostate cancer | |
| CN102120781A (zh) | 一种新型胰岛素口服纳米粒的制备及应用 | |
| CN110167596A (zh) | 用于药物递送和稳定化的复合物及其制备方法 | |
| Kadiyam et al. | Colon specific drug delivery of tramadol HCl for chronotherapeutics of arthritis | |
| Fernandez et al. | In vivo antitumor and Antimetastatic efficacy of a Polyacetal‐based paclitaxel conjugate for prostate cancer therapy | |
| CN103055324B (zh) | 共担载顺铂和阿霉素的复合物、胶束及胶束的制备方法 | |
| WO2001052896A2 (en) | Compositions with enhanced oral bioavailability | |
| CN104367556B (zh) | 一种能提供一氧化氮的透明质酸硝酸酯去氧胆酸聚合物胶束的制备方法及其应用 | |
| JP2003504312A (ja) | 生物学的に活性な材料 | |
| JP2009518406A5 (enExample) | ||
| Ling et al. | Using a peptide segment to covalently conjugate doxorubicin and taxol for the study of drug combination effect | |
| He et al. | Comparison of active and passive targeting of doxorubicin for somatostatin receptor 2 positive tumor models by octreotide-modified HPMA copolymer-doxorubicin conjugates | |
| US20230398067A1 (en) | Metal-organic framework mediated macromolecule delivery system |